TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22471362

Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan (3.75g twice daily for seven days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Keishi-bukuryo-gan
Number of subjects: 31
Study: 20860913

Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg every 4 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18569471

Group type: EXPERIMENTAL
Intervention: Intravaginal Misoprostol 25 microm 4‐hourly
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intracervical dinoprostone 0.5 mg 12 hourly
Number of subjects: 100
Study: 15799717

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (80 mg of caffeine)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Decaffeinated coffee (< 2 mg of caffeine)
Number of subjects: 17
Study: 12447087

Group type: EXPERIMENTAL
Intervention: Force-feedback treatment for lower paretic limb
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Force-feedback treatment for upper paretic limb
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (untreated paretic limb of each group)
Number of subjects: 25
Study: 10351968

Group type: EXPERIMENTAL
Intervention: Patients with EF <50%
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with EF >50%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with EF <50% (n=3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Patients with EF >50% (n=8)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patients with EF <50% (n=12)
Number of subjects: 30
Study: 7485809

Group type: EXPERIMENTAL
Intervention: Cerebral electrical stimulation (CES)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 64
Study: 1743807

Group type: EXPERIMENTAL
Intervention: 100 IU SMC rectally
Number of subjects: 10

Group type: COMPARATOR
Intervention: 50 IU SMC intramuscularly
Number of subjects: 10
Study: 6617596

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Polytherapy (reduction of anticonvulsants)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High serum levels of anticonvulsants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monotherapy (high serum levels)
Number of subjects: 0
Study: 29939243

Group type: EXPERIMENTAL
Intervention: 2-visit intradermal vaccination (2 doses of 0.1 mL ID of HDCV at days 0 and 7)
Number of subjects: 500

Group type: COMPARATOR
Intervention: 3-visit standard vaccination (single dose of 0.1 mL ID at days 0, 7, and 28)
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 500
Study: 26992719

Group type: EXPERIMENTAL
Intervention: Stemmed tibial component (10 mm/100 mm)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard cemented tibial component
Number of subjects: 120
Study: 25428755

Group type: EXPERIMENTAL
Intervention: Ropivacaine (7.5 mg/mL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: NaCl (9 mg/mL)
Number of subjects: 200
Study: 23494090

Group type: EXPERIMENTAL
Intervention: TCI Loop
Number of subjects: 36

Group type: COMPARATOR
Intervention: TCI Manual
Number of subjects: 36
Study: 21350038

Group type: EXPERIMENTAL
Intervention: Exemplary care (EC)
Number of subjects: 0
Study: 19516153

Group type: EXPERIMENTAL
Intervention: Q‐EGCG
Number of subjects: 39
Study: 17309378

Group type: EXPERIMENTAL
Intervention: Massage therapy (20 minutes of massage on five occasions)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (five 20-minute visits)
Number of subjects: 39
Study: 15638352

Group type: EXPERIMENTAL
Intervention: Double-pump (DP) syringe change
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-pump (SP) syringe change
Number of subjects: 0
Study: 11386490

Group type: EXPERIMENTAL
Intervention: d-amphetamine (10-20 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: methylphenidate (20-40 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: methylphenidate and d-amphetamine
Number of subjects: 8
Study: 9595975

Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo MRI
Number of subjects: 5
Study: 8187012

Group type: EXPERIMENTAL
Intervention: New pharmaceutical agents
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Economic and clinical data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase III clinical trials
Number of subjects: 0
Study: 3046283

Group type: EXPERIMENTAL
Intervention: APSAC (30 U as intravenous injection)
Number of subjects: 313

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: APSAC
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: APSAC and Heparin
Number of subjects: 313
Study: 30721549

Group type: EXPERIMENTAL
Intervention: Growth hormone therapy (GH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27463698

Group type: EXPERIMENTAL
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study: 25789978

Group type: EXPERIMENTAL
Intervention: Jasmine rice
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Basmati rice
Number of subjects: 75
Study: 22999815

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Printed literature about alcohol and drug use risks (Control)
Number of subjects: 104
Study: 21701341

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment at 59 J/cm
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-intensity focused ultrasound treatment at 47 J/cm
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham control (0 J/cm)
Number of subjects: 100
Study: 20175279

Group type: COMPARATOR
Intervention: norbactin (norfloxacin) 400 mg twice a day for 7 days
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: furamag 50 mg 3 times a day for 10 days
Number of subjects: 82
Study: 16944396

Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone (Pred)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 20 mg prednisolone plus 4 mg salbutamol (Pred-Sal)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo (Pla)
Number of subjects: 7
Study: 14996262

Group type: EXPERIMENTAL
Intervention: Parental presence during emergence from anaesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (parent present only at induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Both groups (study and control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children described as clingy/dependent
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Children with frequent temper tantrums
Number of subjects: 100
Study: 11334659

Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 34
Study: 9107384

Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Foscarnet (PFA)
Number of subjects: 29
Study: 7698307

Group type: EXPERIMENTAL
Intervention: Orion Video Home-Training Project
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 116
Study: 2966140

Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg on induction of anaesthesia and 200 mg 24 h later)
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Teicoplanin (three doses of 400 mg)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Tobramycin (80 mg tds for three days) and flucloxacillin (500 mg qds for 5 days)
Number of subjects: 517
Study: 30904221

Group type: EXPERIMENTAL
Intervention: Protein-enriched formula (PDF)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Standard term formula (TF)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Human milk (HM)
Number of subjects: 152
Study: 30254744

Group type: EXPERIMENTAL
Intervention: DHS5 survey questions
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: MICS5 survey questions
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Use of medicine pill boards
Number of subjects: 604
Study: 27107960

Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (spinal manipulation, spinal mobilization, stretching and massage)
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Naprapathic manual therapy excluding spinal manipulation
Number of subjects: 1057

Group type: COMPARATOR
Intervention: Naprapathic manual therapy excluding stretching
Number of subjects: 1057

Group type: EXPERIMENTAL
Intervention: Naprapathic manual therapy (all groups)
Number of subjects: 1057
Study: 24812023

Group type: EXPERIMENTAL
Intervention: 12-week exercise intervention
Number of subjects: 61

Group type: COMPARATOR
Intervention: 12-week health education contact control
Number of subjects: 61
Study: 22492171

Group type: EXPERIMENTAL
Intervention: Anterior Pelvic External Fixation (APEF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Anterior Pelvic Internal Fixation (APIF)
Number of subjects: 11
Study: 19218249

Group type: EXPERIMENTAL
Intervention: Nadolol + Isosorbide-5-mononitrate alone (Drug)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Nadolol + Isosorbide-5-mononitrate combined with EBL (Drug + EBL)
Number of subjects: 158
Study: 17204097

Group type: EXPERIMENTAL
Intervention: Serial glycolic acid peels, topical azelaic acid 20% cream (b.i.d.), and adapalene 0.1% gel (q.i.d.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Topical azelaic acid and adapalene (control group)
Number of subjects: 28
Study: 15085092

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12504397

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2) intravenously every 3 months for 24 months
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Mitoxantrone 12 mg/m(2)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194
Study: 10422931

Group type: EXPERIMENTAL
Intervention: 500 microg neostigmine in the axillary plexus and saline solution subcutaneously (group 2)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Saline solution in the axillary plexus and 500 microg neostigmine subcutaneously (group 3)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Saline solution in the axillary plexus and subcutaneously (group 1)
Number of subjects: 69
Study: 7744537

Group type: EXPERIMENTAL
Intervention: Delayed percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 23
Study: 2399493

Group type: EXPERIMENTAL
Intervention: Poly-soft (PS) X-ray film packets
Number of subjects: 25

Group type: COMPARATOR
Intervention: Paper-pack (PP) X-ray film packets
Number of subjects: 25
Study: 401005

Group type: EXPERIMENTAL
Intervention: Papaverine (150 mg BID for 1 week, then 300 mg BID for 5 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No drug (6-week no drug control condition)
Number of subjects: 41
Study: 28413925

Group type: EXPERIMENTAL
Intervention: Triple-bead mixed amphetamine salts (MAS) 25, 50, or 75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31514391

Group type: EXPERIMENTAL
Intervention: Diabetes Community Sharp Disposal Education Module
Number of subjects: 132
Study: 28101779

Group type: EXPERIMENTAL
Intervention: Topical EMLA with breastfeeding (EB group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray with breastfeeding (VB group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Only breastfeeding (BO group)
Number of subjects: 90
Study: 26481581

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by a case manager in the primary care setting
Number of subjects: 33
Study: 25136638

Group type: EXPERIMENTAL
Intervention: Omega-3 tablets (2.4 gr/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Vitamin E tablets (400 IU/day)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 22524471

Group type: EXPERIMENTAL
Intervention: Parotid gland massage
Number of subjects: 60

Group type: COMPARATOR
Intervention: No massage (Control)
Number of subjects: 60
Study: 19348541

Group type: EXPERIMENTAL
Intervention: Viewing very cute images (puppies and kittens)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Viewing slightly cute images (dogs and cats)
Number of subjects: 2
Study: 17068486

Group type: EXPERIMENTAL
Intervention: Free SCs intervention (FS)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Same free SCs with explicit labeling (FNL)
Number of subjects: 364

Group type: COMPARATOR
Intervention: No intervention (NI)
Number of subjects: 364
Study: 15338687

Group type: EXPERIMENTAL
Intervention: Intravenous calcitriol therapy (Group III)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Oral calcitriol therapy (Group II)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No calcitriol therapy (Group I)
Number of subjects: 24
Study: 11229829

Group type: EXPERIMENTAL
Intervention: Garlic oil (GO) capsules, 12.3 mg/day for 16 weeks
Number of subjects: 27
Study: 9594353

Group type: EXPERIMENTAL
Intervention: Chronic hypoxia at high altitude (5,050 m) for thirty-four days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sea level
Number of subjects: 9
Study: 7735929

Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 3 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Combination therapy with clarithromycin (200 mg, three times a day) + sofalcone (100 mg, three times a day) for 2 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination therapy with clarithromycin + sofalcone
Number of subjects: 42
Study: 1976379

Group type: EXPERIMENTAL
Intervention: Terfenadine 40 mg
Number of subjects: 86

Group type: COMPARATOR
Intervention: Pseudoephedrine 60 mg
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Combination of terfenadine 40 mg and pseudoephedrine 60 mg
Number of subjects: 86
Study: 380580

Group type: EXPERIMENTAL
Intervention: 5 mg of diazepam
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 2.5 mg of Bay g 5653
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 5 mg of Bay g 5653
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: 10 mg of Bay g 5653
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 31089108

Group type: EXPERIMENTAL
Intervention: Cefaly device stimulation of the supraorbital nerve
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28059806

Group type: EXPERIMENTAL
Intervention: 6 Hz transcranial alternating current stimulation (tACS) for frontoparietal network desynchronization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 26096765

Group type: EXPERIMENTAL
Intervention: AZD6482 + aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI3Kβ inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P2Y12 + PI3Kβ
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: P2Y12 + COX‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PI3Kβ + COX‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy (P2Y12 + PI3Kβ + COX‐1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6482
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel + aspirin
Number of subjects: 0
Study: 23497759

Group type: EXPERIMENTAL
Intervention: Orally disintegrating film (ODF) formulation of sildenafil, 50 mg (part 1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) formulation of sildenafil, 50 mg (part 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Orally disintegrating film (ODF) formulation of sildenafil, 100 mg (part 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Film-coated tablet (FCT) formulation of sildenafil, 100 mg (part 2)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) with ODF and FCT formulations
Number of subjects: 120
Study: 21692601

Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 19622998

Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 2
Study: 18090169

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (1200 mg every 12 hrs, starting immediately before cardiac surgery)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 254
Study: 15200747

Group type: EXPERIMENTAL
Intervention: Combination therapy (CT) with nateglinide (120 mg, ac) and metformin (500 mg, tid)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Number of subjects: 401

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 401
Study: 11115582

Group type: EXPERIMENTAL
Intervention: Radiotherapy with TAI of 120 mg/body cisplatin twice a month at 4-week intervals
Number of subjects: 60

Group type: COMPARATOR
Intervention: Radiotherapy with 200 mg/day oral 5‐FU or UFT every day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival rates
Number of subjects: 60
Study: 9600369

Group type: EXPERIMENTAL
Intervention: Tamoxifen, 40 mg/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 7993983

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Benazepril (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Coadministration of aspirin and benazepril
Number of subjects: 12
Study: 2730972

Group type: EXPERIMENTAL
Intervention: Sensory stimulation protocol
Number of subjects: 45
Study: 7002

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methyprylon
Number of subjects: 30
Study: 11380131

Group type: EXPERIMENTAL
Intervention: Home management (short-arm backslab removed at home after three weeks)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Hospital management (normal practice, attended fracture clinic after three weeks)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both groups' preference for backslab removal
Number of subjects: 87
Study: 31669225

Group type: EXPERIMENTAL
Intervention: Preventive inhalation of hypertonic saline
Number of subjects: 0
Study: 26334244

Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (0.9% saline solution)
Number of subjects: 40
Study: 26272857

Group type: EXPERIMENTAL
Intervention: In-classroom training by an endoscopist with expertise in NBI
Number of subjects: 33

Group type: COMPARATOR
Intervention: Self-directed training with an automated version of the presentation
Number of subjects: 33
Study: 25256893

Group type: EXPERIMENTAL
Intervention: Indocyanine green retention rate at 15 minutes (ICGR15)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Tumour site
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: ICGR15
Number of subjects: 878
Study: 23270328

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19725815

Group type: EXPERIMENTAL
Intervention: Bromfenac sodium ophthalmic solution (BF)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Steroidal solution (ST)
Number of subjects: 62
Study: 17428949

Group type: EXPERIMENTAL
Intervention: Monovalent HPV16 vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quadrivalent HPV vaccine
Number of subjects: 0
Study: 15797982

Group type: EXPERIMENTAL
Intervention: Proparacaine HCl ophthalmic solution 0.5%
Number of subjects: 22

Group type: COMPARATOR
Intervention: NaCl 0.9% (saline) eye drops
Number of subjects: 22
Study: 11970775

Group type: EXPERIMENTAL
Intervention: Beliefs and evaluations framed positively or negatively
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiplicative model
Number of subjects: 0
Study: 9583551

Group type: EXPERIMENTAL
Intervention: Etomidate, 0.3 mg/kg, and fentanyl, 1 microg/kg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ketamine, 1 mg/kg, and fentanyl, 1 microg/kg
Number of subjects: 30
Study: 8580227

Group type: EXPERIMENTAL
Intervention: CI-988 capsules/CCK-4
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules/CCK-4
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo capsules/placebo
Number of subjects: 30
Study: 2679240

Group type: EXPERIMENTAL
Intervention: L-carnitine, 3 g IV as a bolus, followed by continuous intravenous infusion of 2 mg/kg/min for thirty minutes
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1208760

Group type: EXPERIMENTAL
Intervention: Diazepam (0.3 mg/kg)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Scopolamine (8 mug/kg)
Number of subjects: 36
Study: 30977897

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 39
Study: 27865117

Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control group (no intraaortic balloon pump therapy)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Baseline CI levels
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: High CI levels at day 3
Number of subjects: 600
Study: 25859764

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT-SAD) for 6 weeks, 12 sessions in a group format, 90 minutes each, administered by Ph.D. psychologists
Number of subjects: 177

Group type: COMPARATOR
Intervention: Light Therapy for 6 weeks, 10,000-lux cool-white fluorescent light, initiated at 30 minutes each morning
Number of subjects: 177
Study: 24383855

Group type: EXPERIMENTAL
Intervention: T2DM subjects
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: CAD subjects
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: T2DM-CAD subjects
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: IL-12
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: IFN-γ
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: IL-4
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: IL-5
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: IL-13
Number of subjects: 164